Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules

Molecular Neurobiology

Volumn 47, Issue 3, 2013, Pages 1066-1080

  Frozza, Rudimar L ^a   Bernardi, Andressa ^a   Hoppe, Juliana B ^a   Meneghetti, André B ^a   Matté, Aline ^a   Battastini, Ana M O ^a   Pohlmann, Adriana R ^a   Guterres, Sílvia S ^a   Salbego, Christianne ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Alzheimer's disease; Amyloid peptide; Drug delivery; Hippocampus; Neuroprotection; Resveratrol

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LIPID; NANOCAPSULE; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN TISSUE; ENZYME ACTIVATION; LEARNING; MALE; MEMORY; MICROGLIA; NEUROPROTECTION; NONHUMAN; RAT; ANIMAL; CELL PROTECTION; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HIPPOCAMPUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEMORY DISORDER; METABOLISM; PATHOLOGY; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SYNAPSE; TISSUE DISTRIBUTION; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BETA CATENIN; CYTOPROTECTION; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPIDS; MALE; MEMORY DISORDERS; MICROGLIA; NANOCAPSULES; NEUROPROTECTIVE AGENTS; PROTEIN STABILITY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STILBENES; SYNAPSES; TISSUE DISTRIBUTION;

EID: 84887293638     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8401-2     Document Type: Article

References (78)

1. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639
2. Klein WL, Stine WB Jr, Teplow D.B. (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-580
3. Walsh DM, Selkoe D.J. (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193
4. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14
5. Modi G, Pillay V, Choonara Y.E., Ndesendo VMK, du Toit LC, Naidoo D (2009) Nanotechnological applications for the treatment of neurodegenerative disorders. Progress Neurobiol 88:272-285
6. Hans ML, Lowman A.M. (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319-327
7. Soppimath KS, Aminabhavi TM, Kulkarni A.R., Rudzinski W.E. (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1-20
8. Zensi A, Begley D, Pontikis C., Legros C, Mihoreanu L, Wagner S., Büchel C, von Briesen H, Kreuter J (2009) Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons. J Control Release 137:78-86
9. Brasnjevic I, Steinbusch HWM, Schmitz C, Martinez-Martinez P (2009) Delivery of peptide and protein drugs over the blood-brain barrier. Progress Neurobiol 87:212-251
10. Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B. (2010) Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 6:144-152
11. Guterres SS, Weiss V, de Luca Freitas L, Pohlmann AR (2000) Influence of benzyl benzoate as oil core on the physicochemical properties of spray-dried powders from polymeric nanocapsules containing indomethacin. Drug Deliv 7:195-199
12. Pohlmann AR, Soares LU, Cruz L, Da Silveira NP, Guterres S.S. (2004) Diffusion and mathematical modeling of release profiles from nanocarriers. Curr Drug Deliv 1:103-110
13. Beck RCR, Pohlmann AR, Hoffmeister C, Gallas M.R., Collnot E., Schaefer UF, Guterres SS, Lehr C.M. (2007) Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell mono-layers. Eur J Pharm Biopharm 67:8-30
14. Pohlmann AR, Mezzalira G, Venturini C., Cruz L, Bernardi A, Jäger E, Battastini AMO, Silveira NP, Guterres SS (2008) Determining the simultaneous presence of drug nanocrystals in drug-loaded polymeric nanocapsule aqueous suspensions: a relation between light scattering and drug content. Int J Pharmac 359:288-293
15. Bernardi A, Braganhol E, Jäger E, Figueiró F, Edelweiss MI, Pohlmann AR, Guterres SS, Battastini AMO (2009) Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 281:53-63
16. Frozza RL, Bernardi A, Paese K., Hoppe JB, da Silva T, Battastini AMO, Pohlmann AR, Guterres SS, Salbego C (2010) Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol 6:694-703
17. Bernardi A, Frozza RL, Meneghetti A, Hoppe J.B., Battastini AM, Pohlmann AR, Guterres SS, Salbego C.G. (2012) Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine 7:4927-4942
18. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L., Commenges D, Salomon R, Renaud S., Breteler M.B. (1997) Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol 153:185-192
19. Lindsay J, Laurin D, Verreault R., Hébert R, Helliwell B., Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156:445-453
20. Vingtdeux V, Dreses-Werringloer U, Zhao H., Davies P, Marambaud P. (2008) Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 9 (Suppl 2):S6, Review
21. Anekonda TS (2006) Resveratrol-A boon for treating Alzheimer's disease? Brain Res Rev 52:316-326
22. Harikumar KB, Aggarwal B.B. (2008) Resveratrol A multi-targeted agent for age-associated chronic diseases. Cell Cycle 8:1020-1035
23. Baur JA, Sinclair D.A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506
24. Marambaud P, Zhao H, Davies P. (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280:37377-37382
25. Karuppagounder SS, Pinto JT, Xu H, Chen H.L., Beal MF, Gibson G.E. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54:111-118
26. Vingtdeux V, Giliberto L, Zhao H., Chandakkar P, Wu Q, Simon J.E., Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285:9100-9113
27. Kundu JK, Surh Y-J (2008) Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 296:243-261
28. Knutson MD, Leeuwenburgh C. (2008) Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 66:591-596
29. Albani D, Polito L, Forloni G. (2010) Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis 19:11-26
30. Baur JA, Pearson KJ, Price N.L., Jamieson HA, Lerin C, Kalra A, Prabhu V.V., Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342
31. Wenzel E, Somoza V. (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49:472-481
32. Amri A, Chaumeil JC, Sfar S, Charrueau C. (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158:182-193
33. Jäger E., Venturini CG, Poletto F.S., Colomé LM, Pohlmann JPU, Bernardi A, Battastini AMO, Guterres SS, Pohlmann AR (2009) Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol 5:130-140
34. Paxinos G, Watson C. (2005) The rat brain in stereotaxic coordinates, 5th edn. Elsevier Academic, San Diego
35. Huges RN (2004) The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 28:497-505
36. Bevins RA, Besheer J. (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protocols 1:1306-1311
37. Ennaceur A, Delacour J. (1988) A new one-trial test for neurobio-logical studies of memory in rats. 1. Behavioral data. Behav Brain Res 31:47-59
38. Peterson GL (1979) Review of the Folin-phenol protein quantification method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 100:201-220
39. Zamin LL, Dillenburg-Pilla P, Argenta-Comiran R, Horn AP, Simão F, Nassif M., Gerhardt D, Frozza RL, Salbego C (2006) Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of PI3-K pathway. Neurobiol Dis 24:170-182
40. Garrido JL, Godoy J, Alvarez A., Bronfman M, InestrosaNC (2002) Protein kinase C inhibits amyloid β-peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 14:1982-1984
41. De Ferrari G.V., Chacón MA, Barría MI, Garrido J.L., Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol Psychiatry 8:195-208
42. Li B, Zhong L, Yang X., Andersson T, Huang M, Tang S-J (2011) WNT5A signaling contributes to Aβ-induced neuroinflammation and neurotoxicity. PlosOne 6:1-10
43. Woodruff-Pak DS (2008) Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15:507-521
44. Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and others amyloid diseases. IUBMB Life 59:332-345
45. Knobloch M, Mansuy I.M. (2008) Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol 37:73-82
46. Broadbent NJ, Gaskin S, Squire L.R., Clark R.E. (2010) Object recognition memory and the rodent hippocampus. Learn Mem 17:5-11
47. Scheff SW, Price DA, Schmitt F.A., Mufson E.J. (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27:1372-1384
48. Medeiros R, Prediger RDS, Passos GF, Pandolfo P, Duarte F.S., Franco JL, Dafre AL, Di Giunta G, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB (2007) Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein. J Neurosci 27:5394-5404
49. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 29:14741-14751
50. Passos GF, Figueiredo CP, Prediger RDS, Pandolfo P, Duarte F.S., Medeiros R., Calixto J.B. (2009) Role of the macrophage inflammatory protein-1α/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by β-amyloid peptide. Am J Pathol 175:1586-1597
51. Bernardi A, Zilberstein AC, Jäger E, Campos M.M., Morrone FB, Calixto JB, Pohlmann AR, Guterres S.S., Battastini AMO (2009) Effects of indomethacin-loaded nanocapsules in experimental model of inflammation in rats. Br J Pharmacol 158:1104-1111
52. Bernardi A, Frozza RL, Horn A.P., Campos MM, Calixto JB, Salbego C, Pohlmann A.R., Guterres SS, Battastini AMO (2010) Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int 57:629-636
53. Calamini B, Ratia K, Malkowski M.G., Cuendet M., Pezzuto JM, Santarsiero BD, Mesecar A.D. (2010) Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429(2):273-282
54. Hoshino J, Park EJ, Kondratyuk T.P., Marler L., Pezzuto JM, van Breemen RB, Mo S, Li Y, Cushman M (2010) Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53(13):5033-5043
55. Miksits M, Wlcek K, Svoboda M., Kunert O, Haslinger E, Thalhammer T., Szekeres T, Jäger W (2009) Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med 75(11):1227-1230
56. Walle T (2011) Biovailability of resveratrol. Ann NY Acad Sci 1215:9-15
57. Kreuter J, Alyautdin RN, Kharkevich D.A., Ivanov A.A. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171-174
58. Alyautdin RN, Petrov VE, Langer K, Berthold A., Kharkevich DA, Kreuter J. (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nano-particles. Pharm Res 14:325-328
59. Gulyaev AE, Gelperina SE, Skidan I.N., Antropov AS, Kivman GY, Kreuter J. (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-1569
60. Lue L-F, Kuo Y-M, Beach T, Walker D.G. (2010) Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 41:115-128
61. Hensley K (2010) Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 21:1-14
62. Garwood CJ, Pooler AM, Atherton J, Hanger D.P., Noble W. (2011) Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2:1-9
63. Capiralla H, Vingtdeux V, Zhao H., Sankowski R, Al-Abed Y, Davies P, Marambaud P. (2011) Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 120:461-472
64. Mehan S, Meena H, Sharma D., Sankhla R. (2011) JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci 43:376-390
65. Waetzig V, Herdegen T. (2004) Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci Lett 361:64-67
66. Ploia C, Antoniou X, Sclip A., Grande V, Cardinetti D, Colombo A., Canu N, Benussi L, Ghidoni R, Forloni G, Borsello T (2011) JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J Alzheimers Dis 26:315-329
67. Balaraman Y, Limaye AR, Levey A.I., Srinivasan S. (2006) Glycogen synthase kinase 3β and Alzheimer's disease: pathophys-iological and therapeutic significance. Cell Mol Life Sci 63:1226-1235
68. Hall AC, Lucas FR, Salinas P.C. (2000) Axonal remodeling and synaptic differentiation in the cerebellum is regulated by Wnt-7a signaling. Cell 100:525-535
69. Cadigan KM, Nusse R. (1997) Wnt signaling: a common theme in animal development. Genes Dev 11:3286-3305
70. Lee SM, Tole S, Grove E., McMahon A.P. (2000) A local Wnt-3a signal is required for development of the mammalian hippocampus. Development 127:457-467
71. Galceran J, Miyashita-Lin EM, Devaney E., Rubenstein JL, Grosschedl R. (2000) Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development 127:469-482
72. Liu C, Li Y, Semenov M., Han C, Baeg C, Tan Y., Zhang Z, Lin X, He X (2002) Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847
73. Inestrosa NC, Varela-Nallar L, Grabowski C.P., Colombres M. (2007) Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. IUBMB Life 59:316-321
74. Toledo EM, Inestrosa N.C. (2009) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15:272-285
75. Ge J-F, Qiao J-P, Qi C-C, Wang C-W, Zhou J-N (2012) The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int 61:1192-1201
76. Ladiwala ARA, Lin JC, Bale S.S., Marcelino-Cruz AM, Bhattacharya M, Dordick J.S., Tessier P.M. (2010) Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J Biol Chem 285:24228-24237
77. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17(9):1060-1065
78. Mucke L, Selkoe D.J. (2012) Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2(7):a006338